If carriage of specific alleles truly affects response to IFN, and IFN therapy changes the natural history of chronic viral hepatitis, therefore patients with favorable alleles would have mild outcome, while patients with unfavorable alleles would progress to worse outcome. The gene discussed is IFNA1; the disease is animal viral hepatitis.